Circulating free DNA and circulating tumor cells as new serum biomarkers in advanced ovarian cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 5566-5566
Author(s):  
Jeronimo Martinez Garcia ◽  
Asuncion Soto ◽  
Pilar Sanchez-Henarejos ◽  
Ana Puertes Boix ◽  
Edith Rodriguez ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Malignant Tumors ◽  
Area Under The Curve ◽  
Advanced Ovarian Cancer ◽  
Control Group ◽  
Central Research ◽  
Circulating Free Dna ◽  
Free Dna ◽  
New Biomarkers

5566 Background: Circulating free DNA (cfDNA) and circulating tumor cells (CTC) are new biomarkers for malignant tumors. Its role on ovarian epithelial cancer (OEC) is not yet well stablished. We analyze its role on advanced OEC compared with CA125 and HE4. Methods: Multicentric prospective observational study from November 2013 until February 2017, with OEC patients group (OECG), benign ovarian tumors group (BENIGNG) and health subjects control group (HEALTHG). CTCs were analysed by the CellSearch method and cfDNA by ALU-sequences-based quantitative PCR using two primers (115 and 247 bp); cfDNA integrity was calculated by ALU247/ALU115 ratio. Samples were obtained before treatment (M0), after primary peritoneal surgery (M1), after one cycle of chemotherapy (M2), before (M3) and after interval surgery (M4). This study was approved on May 2013 by the corresponding Central Research Independent Ethics Committee. Results: We analyized 102 subjects from all 3 groups (81 OECG, 14 BENIGNG y 7 HEALTHG); 68% were high grade serous subtype; most frequent staging was IIIC (58%). Within the follow-up (FU) period (average 14 months: min 0, max. 35) 36% relapses and 23% deaths were reported. CTCs were positive on 23% of OECG. In HEALTHG no positive were seen and only 1/14 in the BENIGNG group. Monitoring of cfDNA at the treatment points shows significant differences between M0 and M4 (p = 0.02). No differences were seen in the other determinations. cfDNA-ALU115 was 1.40178 ng / mcL (95% CI 1.18066-1.62290) in the OECG, 0.66383 (95% CI 0.44832-0.87935) in BENIGNG and 0.59923 in HEALTHG ( 95% CI, 0.14449-1.05397). The difference was significant between OECG and BENIGNG (P = 0.017) and near the significance between OECG and HEALTHG (p = 0.69). cfDNA integrity in OECG and HEALTHG was significantly different (P = .012). The area under the curve of Ca125, HE4, CTC, cfDNA and CFDNA integrity was 0.490, 0.526, 0.621, 0.587 and 0.450 respectively. New generation sequencing of circulating TP53 is ongoing. Conclusions: CTC and cfDNA are new biomarkers that might have an important role in the diagnosis and monitoring of OEC.

scholarly journals Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer

2022 ◽  
Vol 2022 ◽  
pp. 1-9
Author(s):  
Pengjie Yu ◽  
Shengmao Zhu ◽  
Yushuang Luo ◽  
Ganggang Li ◽  
Yongqiang Pu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Neoadjuvant Therapy ◽  
Advanced Gastric Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Circulating Free Dna ◽  
Free Dna ◽  
N Stage

Objective. To explore the application value of circulating tumor cells (CTCs) and circulating free DNA (cfDNA) from peripheral blood in the prognosis of advanced gastric cancer (AGC). Here, we measured CTCs and cfDNA quantity for predicting the outcome of patients. Patients and Methods. Forty-five patients with advanced gastric cancer who underwent neoadjuvant chemotherapy and surgical treatment were enrolled in this study. All patients received neoadjuvant chemotherapy with paclitaxel + S-1 + oxaliplatin (PSOX) regimen, and CTCs and cfDNA of the peripheral blood were detected before and after neoadjuvant therapy. Relationships between the number/type of CTC or cfDNA and the efficacy of neoadjuvant chemotherapy were analyzed. Results. Among 45 patients, 43 (95.6%) were positive, and the positive rate of mesenchymal CTC was increased with the increase in the T stage. The proportion of mesenchymal CTC was positively correlated with the N stage ( P < 0.05 ), and the larger N stage will have the higher proportion of mesenchymal CTC. Patients with a small number of mesenchymal CTC before neoadjuvant chemotherapy were more likely to achieve partial response (PR) with neoadjuvant therapy. Patients with positive CA-199 were more likely to achieve PR with neoadjuvant therapy ( P < 0.05 ). Patients in the PR group were more likely to have decreased/unchanged cfDNA concentration after neoadjuvant therapy ( P = 0.119 ). After neoadjuvant therapy (before surgery), the cfDNA concentration was higher and the efficacy of neoadjuvant therapy (SD or PD) was lower ( P = 0.045 ). Conclusions. Peripheral blood CTC, especially interstitial CTC and cfDNA, has a certain value in predicting the efficacy and prognosis of neoadjuvant chemotherapy in advanced gastric cancer.

scholarly journals Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

Cells ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 522 ◽  
Author(s):  
Patricia Mondelo-Macía ◽  
Carmela Rodríguez-López ◽  
Laura Valiña ◽  
Santiago Aguín ◽  
Luis León-Mateos ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Copy Number ◽  
Patients With Cancer ◽  
Circulating Free Dna ◽  
Free Dna ◽  
Met Amplification ◽  
Potential Biomarker

MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alterations in cancer patients. We analyzed MET amplification in circulating free DNA (cfDNA) from 174 patients with cancer and 49 healthy controls and demonstrated the accuracy of the analysis to detect its alteration in patients. Importantly, a significant correlation between cfDNA concentration and MET copy number (CN) in cancer patients (r = 0.57, p <10−10) was determined. Furthermore, we evaluated two approaches to detect the presence of MET on circulating tumor cells (CTCs), using the CellSearch® and Parsortix systems and monitored patients under anti-EGFR treatment (n = 30) combining both cfDNA and CTCs analyses. This follow-up provides evidence for the potential of MET CN assessment when patients develop resistance to anti-EGFR therapy and a significant association between the presence of CTCs MET+ and the Overall Survival (OS) in head and neck cancer patients (P = 0.05; HR = 6.66). In conclusion, we develop specific and noninvasive assays to monitor MET status in cfDNA/CTCs and demonstrate the utility of plasma MET CN determination as a biomarker for monitoring the appearance of resistance to anti-EGFR therapy.

scholarly journals Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?

2017 ◽  
Vol 41 (2) ◽  
pp. 755-768 ◽  
Author(s):  
Wei Zhang ◽  
Wenjie Xia ◽  
Zhengye Lv ◽  
Chao Ni ◽  
Yin Xin ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Tumor Development ◽  
Prognostic Information ◽  
Source Characteristics ◽  
Circulating Free Dna ◽  
Free Dna ◽  
And Personalized Medicine

Precision medicine and personalized medicine are based on the development of biomarkers, and liquid biopsy has been reported to be able to detect biomarkers that carry information on tumor development and progression. Compared with traditional ‘solid biopsy’, which cannot always be performed to determine tumor dynamics, liquid biopsy has notable advantages in that it is a noninvasive modality that can provide diagnostic and prognostic information prior to treatment, during treatment and during progression. In this review, we describe the source, characteristics, technology for detection and current situation of circulating tumor cells, circulating free DNA and exosomes used for diagnosis, recurrence monitoring, prognosis assessment and medication planning.

scholarly journals P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab

2018 ◽  
Vol 13 (10) ◽  
pp. S730-S731
Author(s):  
G. Rossi ◽  
M. Tagliamento ◽  
A. Alama ◽  
S. Coco ◽  
C. Genova ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Predictive Value ◽  
Circulating Free Dna ◽  
Free Dna ◽  
Nsclc Patients

scholarly journals Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
S. Manier ◽  
J. Park ◽  
M. Capelletti ◽  
M. Bustoros ◽  
S. S. Freeman ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Exome Sequencing ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Whole Exome Sequencing ◽  
Cell Free Dna ◽  
Free Dna ◽  
Whole Exome

scholarly journals Detection of Circulating Tumor Cells and Its Application in Prostate Cancer

2020 ◽  
Vol 4 (1) ◽  
pp. 3-7
Author(s):  
Jin-Qi Song ◽  
Ya-Nan Zhou ◽  
Gang-Liang Tu ◽  
Chang-Li Xu ◽  
Hui Xu
Keyword(s):  
Prostate Cancer ◽  
Early Diagnosis ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Malignant Tumors ◽  
Depth Study ◽  
Tumor Research ◽  
The Common ◽  
Development And Evolution

In recent years, circulating tumor cells have become the focus of tumor research. In-depth study of the role of circulating tumor cells in the genesis, development, and evolution of tumors will be of great significance for the early detection, early diagnosis, early treatment, and prognosis of tumors. Prostate cancer is one of the common male malignant tumors, and the role of circulating tumor cells in prostate cancer has been increasing year by year. This article will focus on the progress of circulating tumor cells detection and its application in prostate cancer.

scholarly journals Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives

Cancers ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1659 ◽  
Author(s):  
Verena Martini ◽  
Sylvia Timme-Bronsert ◽  
Stefan Fichtner-Feigl ◽  
Jens Hoeppner ◽  
Birte Kulemann
Keyword(s):  
Pancreatic Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Prognostic Markers ◽  
Cancer Prognosis ◽  
Detection Methods ◽  
Ductal Adenocarcinoma ◽  
Detection Tool ◽  
The Usa ◽  
New Biomarkers

Pancreatic cancer is the fourth leading cause of cancer-related death in the USA and Europe; early symptoms and screenings are lacking, and it is usually diagnosed late with a poor prognosis. Circulating tumor cells (CTCs) have been promising new biomarkers in solid tumors. In the last twenty years (1999–2019), 140 articles have contained the key words “Circulating tumor cells, pancreatic cancer, prognosis and diagnosis.” Articles were evaluated for the use of CTCs as prognostic markers and their correlation to survival in pancreatic ductal adenocarcinoma (PDAC). In the final selected 17 articles, the CTC detection rate varied greatly between different enrichment methodologies and ranged from 11% to 92%; the majority of studies used the antigen-dependent CellSearch© system for CTC detection. Fifteen of the reviewed studies showed a correlation between CTC presence and a worse overall survival. The heterogeneity of CTC-detection methods and the lack of uniform results hinder a comparison of the evaluated studies. However, CTCs can be detected in pancreatic cancer and harbor a hope to serve as an early detection tool. Larger studies are needed to corroborate CTCs as valid biomarkers in pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document